Research programme: anticancer therapeutics - Ablynx/Genencor

Drug Profile

Research programme: anticancer therapeutics - Ablynx/Genencor

Alternative Names: Research programme: anticancer nanobodies - Ablynx/Genencor

Latest Information Update: 18 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx; Genencor International
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 18 May 2006 Discontinued - Preclinical for Solid tumours in USA (Injection)
  • 13 Jun 2005 Genencor International has been acquired by Danisco A/S
  • 29 Sep 2004 Preclinical trials in Solid tumours in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top